Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND +2.89%11 OCF Yield % is -34.66 as of Jul. 29, 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, Vyome Holdings ranks worse than 77.84% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vyome Holdings OCF Yield % Related Terms
Vyome Holdings OCF Yield % Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vyome Holdings's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a OCF Yield % of -34.66 as of Jul. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vyome Holdings and its competitors. According to the industry distribution chart, Vyome Holdings ranks #1096 out of 1408 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Vyome Holdings' OCF Yield % too high?
Vyome Holdings' current OCF Yield % is -34.66. Based on the distribution chart, Vyome Holdings ranks #1096 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' OCF Yield % compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #1096 out of 1408 companies for OCF Yield %. This places Vyome Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current OCF Yield % is -34.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current OCF Yield % of -34.66. The current OCF Yield % is -34.66. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Vyome Holdings (HIND), the current OCF Yield % is -34.66 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
